PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 118 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2021. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $600,000 | -8.4% | 85,600 | +20.1% | 0.01% | 0.0% |
| Q2 2021 | $655,000 | -7.2% | 71,300 | -1.8% | 0.01% | -14.3% |
| Q1 2021 | $706,000 | +19.5% | 72,600 | +26.0% | 0.01% | +16.7% |
| Q4 2020 | $591,000 | +7.7% | 57,600 | +5.9% | 0.01% | 0.0% |
| Q3 2020 | $549,000 | -5.8% | 54,400 | -2.7% | 0.01% | -14.3% |
| Q2 2020 | $583,000 | +540.7% | 55,900 | +417.6% | 0.01% | +600.0% |
| Q1 2020 | $91,000 | -91.2% | 10,800 | -52.2% | 0.00% | -91.7% |
| Q3 2018 | $1,036,000 | -22.5% | 22,600 | 0.0% | 0.01% | -25.0% |
| Q2 2018 | $1,337,000 | -6.9% | 22,600 | +7.1% | 0.02% | -5.9% |
| Q1 2018 | $1,436,000 | +3.0% | 21,100 | +49.6% | 0.02% | +6.2% |
| Q4 2017 | $1,394,000 | -4.6% | 14,100 | +15.6% | 0.02% | -11.1% |
| Q3 2017 | $1,461,000 | +203.7% | 12,200 | +121.8% | 0.02% | +200.0% |
| Q2 2017 | $481,000 | +29.6% | 5,500 | -54.5% | 0.01% | +20.0% |
| Q4 2016 | $371,000 | -54.3% | 12,100 | 0.0% | 0.01% | -58.3% |
| Q3 2016 | $811,000 | – | 12,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 507,500 | $121,074,000 | 24.90% |
| BB BIOTECH AG | 476,991 | $113,796,000 | 4.63% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $1,356,668,000 | 3.35% |
| WEATHERBIE CAPITAL, LLC | 101,055 | $24,109,000 | 2.26% |
| Avalon Global Asset Management LLC | 16,000 | $3,817,000 | 2.24% |
| Redmile Group, LLC | 51,025 | $12,173,000 | 1.41% |
| Fernwood Investment Management, LLC | 6,700 | $1,598,000 | 1.38% |
| Iguana Healthcare Management, LLC | 10,000 | $2,386,000 | 1.27% |
| LMR Partners LLP | 56,632 | $13,510,000 | 1.08% |
| FRANKLIN STREET ADVISORS INC /NC | 21,990 | $5,246,000 | 1.00% |